ProCE Banner Activity

CME

Exploring the Abundance of Biomarkers in Lung Cancer: Current Applications and Future Prospects for Precision Medicine

Multimedia
Watch this on-demand webcast of a live CCO webinar where clinical experts review the latest clinical data, including from ASCO 2021, on optimal use of predictive biomarkers to guide treatment decisions in the management of advanced NSCLC through a series of roundtable discussions.

Physicians: Maximum of 2.00 AMA PRA Category 1 Credits

Released: July 26, 2021

Expiration: July 25, 2022

No longer available for credit.

Share

Faculty

Suresh S. Ramalingam

Suresh S. Ramalingam, MD

Associate Professor
Director,
Division of Medical Oncology
Emory University, Winship Cancer Institute
Atlanta, Georgia

Stephen Liu

Stephen Liu, MD

Assistant Professor of Medicine
Department of Medical Oncology
Lombardi Comprehensive Cancer Center
Georgetown University
Washington, DC

Lecia V. Sequist

Lecia V. Sequist, MD, MPH

The Landry Family Professor of Medicine
Harvard Medical School
Director, Center for Innovation in Early Cancer Detection
Massachusetts General Hospital
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

Turning Point Therapeutics Inc

Target Audience

This program is intended for physicians and other healthcare providers who care for patients with non-small-cell lung cancer.

Learning Objectives

Upon completion of this activity, participants should be able to:
  • Assess new and emerging predictive biomarkers to guide precision treatment decisions in patients with NSCLC
  • Discuss the practical aspects of biomarker testing and interpretation, including benefits/limitations of different testing methodologies/platforms/assays and other nuances
  • Summarize the available data and expert recommendations to determine which biomarkers should be tested in your patients with lung cancer
  • Identify patients eligible for ongoing clinical trials of emerging biomarkers for NSCLC

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Program Director Disclosure

Program Director

Suresh S. Ramalingam, MD

Associate Professor
Director,
Division of Medical Oncology
Emory University, Winship Cancer Institute
Atlanta, Georgia

Suresh S. Ramalingam, MD, FACP, FASCO, has disclosed that he has received consulting fees from Amgen, AstraZeneca, Bristol-Myers Squibb, Daiichi Sankyo, Eisai, Genentech/Roche, GlaxoSmithKline, Lilly, Merck, Sanofi, and Takeda and funds for research support from Advaxis, Amgen, AstraZeneca, Bristol-Myers Squibb, Genmab, GlaxoSmithKline, Merck, Takeda, and Tesaro.

Faculty Disclosure

Primary Author

Stephen Liu, MD

Assistant Professor of Medicine
Department of Medical Oncology
Lombardi Comprehensive Cancer Center
Georgetown University
Washington, DC

Stephen V. Liu, MD, has disclosed that he has received consulting fees from Amgen, AstraZeneca, BeiGene, Blueprint, Bristol-Myers Squibb, Daiichi Sankyo, G1 Therapeutics, Genentech/Roche, Guardant Health, Inivata, Janssen, Jazz, Lilly, Merck/MSD, PharmaMar, Pfizer, Regeneron, and Takeda and funds for research support from Alkermes, Bayer, Blueprint, Bristol-Myers Squibb, Corvus, Debiopharm, Elevation Oncology, Genentech, Lilly, Merck, Merus, Pfizer, Rain Therapeutics, RAPT, and Turning Point Therapeutics.

Lecia V. Sequist, MD, MPH

The Landry Family Professor of Medicine
Harvard Medical School
Director, Center for Innovation in Early Cancer Detection
Massachusetts General Hospital
Boston, Massachusetts

Lecia V. Sequist, MD, MPH, has disclosed that she has received consulting fees from AstraZeneca, Janssen, Genentech, and Pfizer and funds for research support from AstraZeneca, Boehringer Ingelheim, Genentech, Loxo Oncology, and Novartis.

Staff Disclosure

Staff

Rachael M. Andrie, PhD

Clinical Editor

Rachael M. Andrie, PhD, has no relevant conflicts of interest to report.

Gordon Kelley,

Clinical Editor
Clinical Care Options, LLC

Gordon Kelley has no relevant conflicts of interest to report.

Krista Marcello,

Associate Managing Editor

Krista Marcello has no relevant conflicts of interest to report.

Jim Mortimer,

Product Director, Hematology/Oncology
Clinical Care Options, LLC

Jim Mortimer has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Shara Pantry, PhD

Associate Scientific Director

Shara Pantry, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.

Instructions for Credit

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation

CCO designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Additional Information

Participation in this self-study activity should be completed in approximately 2 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from July 26, 2021, through July 25, 2022:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.

Program Medium

This program has been made available online.


Goal


The goal of this activity is to educate physicians and other healthcare professionals about the recent improvements in the care of NSCLC and applying those improvements to their patients.